Delvin Formulations Profile
Key Indicators
- Authorised Capital ₹ 3.25 Cr
- Paid Up Capital ₹ 2.28 Cr
- Company Age 15 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 27.37 Cr
- Revenue Growth 25.51%
- Profit Growth 67.94%
- Ebitda 25.74%
- Net Worth 100.78%
- Total Assets 5.90%
About Delvin Formulations
Delvin Formulations Private Limited (DFPL) is Amalgamated company established on 24 Jul 2009 with its office registered at Kanchipuram, Tamil Nadu, India and has been running since 15 Year, 7 Months with a paid up capital of 2.28 Cr. According to MCA records, 4 Directors are linked to this company as of 18 Jan 2025.
Company Details
- Location
Kanchipuram, Tamil Nadu, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U24100TN2009PTC072376
- Company No.
072376
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
24 Jul 2009
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Pharma
What products or services does Delvin Formulations Private Limited offer?
Delvin Formulations Private Limited offers a wide range of products and services, including Health Conditions, Stomach Care, Respiratory Care, Cold & Cough.
Who are the key members and board of directors at Delvin Formulations?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shanmugam Muthusamy  | Director | 24-Jul-2009 | Current |
Jaganathan Jayaseelan  | Director | 24-Jul-2009 | Current |
| Bernice Sugirtha | Director | 14-Dec-2020 | Current |
| Ayyavu Rajavel | Alternate Director | 13-Aug-2009 | Current |
Financial Performance of Delvin Formulations.
Delvin Formulations Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 25.51% increase. The company also saw a substantial improvement in profitability, with a 67.94% increase in profit. The company's net worth Soared by an impressive increase of 100.78%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Delvin Formulations?
In 2023, Delvin Formulations had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Saimirra Innopharm Private LimitedJaganathan Jayaseelan, Bernice Sugirtha and 2 more are mutual person
Hibrow Healthcare Private LimitedJaganathan Jayaseelan is a mutual person
Inventz Life Sciences Private LimitedJaganathan Jayaseelan is a mutual person
- Delvin Surgicals Private Limited
Jaganathan Jayaseelan and Ayyavu Rajavel are mutual person
Lifespan Wellness Private LimitedJaganathan Jayaseelan is a mutual person
Nuray Chemicals Private LimitedJaganathan Jayaseelan, Ayyavu Rajavel and 1 more are mutual person
Charges (Loans)
Open Charges
₹0
Satisfied Charges
₹27.37 Cr
Charges Breakdown by Lending Institutions
- Others : 11.91 Cr
- Hdfc Bank Limited : 11.45 Cr
- State Bank Of India : 4.00 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 10 Oct 2022 | Others | ₹10.44 Cr | Satisfied |
| 20 May 2019 | Others | ₹0.09 M | Satisfied |
| 14 Feb 2019 | Others | ₹2.35 M | Satisfied |
| 01 Jun 2018 | Others | ₹2.31 M | Satisfied |
| 30 Jan 2017 | Hdfc Bank Limited | ₹11.45 Cr | Satisfied |
How Many Employees Work at Delvin Formulations?
Delvin Formulations has a workforce of 219 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Delvin Formulations, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Delvin Formulations's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Latest Updates, News, and FAQs on Delvin Formulations
Recent activity within the organization
- Charges
A charge registered on 20 May 2019 via Charge ID 100267035 with Others was fully satisfied on 20 May 2024.
- Charges
A charge registered on 10 Oct 2022 via Charge ID 100624035 with Others was fully satisfied on 11 Oct 2023.
- Annual General Meeting
Delvin Formulations Private Limited last Annual general meeting of members was held on 30 Sep 2023 as per latest MCA records.
- Balance Sheet
Delvin Formulations Private Limited has filed its annual Financial statements for the year ended 31 Mar 2023 with Roc Chennai.
- Charges
A charge registered on 14 Feb 2019 via Charge ID 100243273 with Others was fully satisfied on 15 Mar 2023.
- Charges
A charge registered on 01 Jun 2018 via Charge ID 100184732 with Others was fully satisfied on 15 Mar 2023.
Frequently asked questions
What is the Incorporation or founding date of Delvin Formulations Private Limited?
Delvin Formulations Private Limited was incorporated on 24 Jul 2009.
What is authorized share capital and paid-up capital of Delvin Formulations Private Limited?
The authorized share capital of Delvin Formulations Private Limited is ₹ 3.25 Cr and paid-up capital is ₹ 2.28 Cr.
Who are the current board members & directors of Delvin Formulations Private Limited?
Currently 4 directors are associated with Delvin Formulations Private Limited.
- Jaganathan Jayaseelan
- Bernice Sugirtha
- Ayyavu Rajavel
- Shanmugam Muthusamy
What is the registered address of Delvin Formulations Private Limited?
As per Ministry of Corporate Affairs (Mca), the registered address of Delvin Formulations Private Limited is No 5/A5 3Rd Cross Street Sipcot It Park, Siruseri India, Chingleput, Tamil Nadu, 603103.
What is the corporate identification number (CIN) and company number of Delvin Formulations Private Limited?
The corporate identification number (CIN) of Delvin Formulations Private Limited is U24100TN2009PTC072376 and the company number is 072376 as per Ministry of Corporate Affairs (MCA).
What is the official website of Delvin Formulations Private Limited?
The Official website of Delvin Formulations Private Limited is https://www.delvin.in
What has been the recent revenue trend for Delvin Formulations Private Limited?
According to the financial reports for the fiscal year 2023, the revenue trend for Delvin Formulations Private Limited has risen by 25.51%.
How many employees does Delvin Formulations Private Limited currently have?
As Per 2023 financial reports, 219 employees are currently employed by Delvin Formulations Private Limited.
What change has been observed in the net worth of Delvin Formulations Private Limited, and by what percentage?
The financial reports for the fiscal year 2023 indicates that The net worth of Delvin Formulations Private Limited has experienced an upsurge of 100.78%.
When was the last Balance Sheet of Delvin Formulations Private Limited filed with the ROC?
The most recent Balance Sheet for Delvin Formulations Private Limited was filed with the ROC on 31 Mar 2023.